MedTrace Logo

CT Imaging for Guiding PA-TACE for HCC

NCT06156748 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1770

Last updated 2025-07-28

No results posted yet for this study

Summary

Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.

Conditions

  • Carcinoma, Hepatocellular

Interventions

PROCEDURE

postoperative adjuvant transarterial chemoembolization

HCC patients received hepatectomy and PA-TACE.

Sponsors & Collaborators

  • Zhujiang Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06156748 on ClinicalTrials.gov